Over the past decade, we have made considerable progress in establishing diffuse intrinsic
pontine glioma (DIPG) as a disease entity and developing preclinical tools to interrogate …

Purpose of review This review of diffuse intrinsic pontine glioma (DIPG) provides clinical
background, a systematic approach to diagnosis and initial care, and synthesizes historical …

Purpose: PNOC003 is a multicenter precision medicine trial for children and young adults
with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Patients and Methods: Patients …

Diffuse midline glioma (DMG) is a heterogeneous group of aggressive pediatric brain tumors
with a fatal prognosis. The biological hallmark in the major part of the cases is H3K27 …

Purpose Diffuse intrinsic pontine glioma (DIPG) is the most aggressive primary pediatric
brain tumor, with< 10% of children surviving 2 years. Radiation therapy (RT) remains the …

Simple Summary H3K27M-mutant diffuse midline glioma is a rare childhood cancer
originating in midline brain structures. The H3K27M mutation substitutes an amino acid on …

Pediatric glioblastomas are known to be one of the most dangerous and life-threatening
cancers among many others regardless of the low number of cases reported. The major …

As the field of neuro-oncology makes headway in uncovering the key oncogenic drivers in
pediatric glioma, the role of precision diagnostics and therapies continues to rapidly evolve …

Background Traditionally, within dose-finding clinical trials, treatment toxicity and tolerability
are assessed by clinicians. Research has shown that clinician reporting may have …

Introduction This study investigates the safety, tolerability, and preliminary efficacy of
combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan …